Ann D Kwong

Summary

Affiliation: Vertex Pharmaceuticals
Country: USA

Publications

  1. doi Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus
    Ann D Kwong
    Vertex Pharmaceuticals, Cambridge, Massachusetts, USA
    Nat Biotechnol 29:993-1003. 2011
  2. doi Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors
    Ann D Kwong
    Vertex Pharmaceuticals, Incorporated, 130 Waverly Street, Cambridge, MA 02139, USA
    Curr Opin Pharmacol 8:522-31. 2008
  3. ncbi In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061
    Chao Lin
    Vertex Pharmaceuticals Incorporated, Cambridge, Massachusetts 02139, USA
    J Biol Chem 280:36784-91. 2005
  4. pmc Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease
    Yi Zhou
    Vertex Pharmaceuticals Incorporated, 130 Waverly Street, Cambridge, MA 02139, USA
    Antimicrob Agents Chemother 52:110-20. 2008
  5. pmc VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCv replicon cells
    Kai Lin
    Vertex Pharmaceuticals Incorporated, 130 Waverly Street, Cambridge, MA 02139, USA
    Antimicrob Agents Chemother 50:1813-22. 2006
  6. pmc Compensatory substitutions in the HCV NS3/4A protease cleavage sites are not observed in patients treated unsuccessfully with telaprevir combination treatment
    James C Sullivan
    Vertex Pharmaceuticals Incorporated, 130 Waverly Street, Cambridge, MA 02139, USA
    Virol J 9:147. 2012
  7. doi Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects
    Doug J Bartels
    Department of Infectious Diseases, Vertex Pharmaceuticals, Inc, Cambridge, Massachusetts 02139, USA
    J Infect Dis 198:800-7. 2008
  8. pmc Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment
    Doug J Bartels
    Vertex Pharmaceuticals, Inc, Department of Infectious Diseases, Cambridge, Massachusetts, USA
    J Virol 87:1544-53. 2013
  9. ncbi Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha
    Yi Zhou
    Vertex Pharmaceuticals Inc, Cambridge, Massachusetts 02139, USA
    J Biol Chem 282:22619-28. 2007
  10. pmc A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants
    Bambang S Adiwijaya
    Vertex Pharmaceuticals Incorporated, Cambridge, Massachusetts, United States of America
    PLoS Comput Biol 6:e1000745. 2010

Collaborators

Detail Information

Publications19

  1. doi Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus
    Ann D Kwong
    Vertex Pharmaceuticals, Cambridge, Massachusetts, USA
    Nat Biotechnol 29:993-1003. 2011
    ..Lessons learned from the development of telaprevir suggest that makers of innovative medicines cannot rely solely on traditional drug discovery metrics, but must develop innovative, scientifically guided pathways for success...
  2. doi Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors
    Ann D Kwong
    Vertex Pharmaceuticals, Incorporated, 130 Waverly Street, Cambridge, MA 02139, USA
    Curr Opin Pharmacol 8:522-31. 2008
    ....
  3. ncbi In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061
    Chao Lin
    Vertex Pharmaceuticals Incorporated, Cambridge, Massachusetts 02139, USA
    J Biol Chem 280:36784-91. 2005
    ..Both cross-resistance mutations (A156V and A156T) displayed significantly diminished fitness (or replication capacity) in a transient replicon cell system...
  4. pmc Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease
    Yi Zhou
    Vertex Pharmaceuticals Incorporated, 130 Waverly Street, Cambridge, MA 02139, USA
    Antimicrob Agents Chemother 52:110-20. 2008
    ..Finally, the sensitivity of these replicon variants to alpha interferon or ribavirin remained unchanged compared to that of the wild-type...
  5. pmc VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCv replicon cells
    Kai Lin
    Vertex Pharmaceuticals Incorporated, 130 Waverly Street, Cambridge, MA 02139, USA
    Antimicrob Agents Chemother 50:1813-22. 2006
    ..The combination of VX-950 and alpha interferon also suppressed the emergence of in vitro resistance mutations against VX-950 in replicon cells...
  6. pmc Compensatory substitutions in the HCV NS3/4A protease cleavage sites are not observed in patients treated unsuccessfully with telaprevir combination treatment
    James C Sullivan
    Vertex Pharmaceuticals Incorporated, 130 Waverly Street, Cambridge, MA 02139, USA
    Virol J 9:147. 2012
    ..Mechanisms of fitness compensation may occur in HCV populations upon treatment of HCV protease inhibitors as well...
  7. doi Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects
    Doug J Bartels
    Department of Infectious Diseases, Vertex Pharmaceuticals, Inc, Cambridge, Massachusetts 02139, USA
    J Infect Dis 198:800-7. 2008
    ..We report here the prevalence of such variants and their effect on clinical response...
  8. pmc Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment
    Doug J Bartels
    Vertex Pharmaceuticals, Inc, Department of Infectious Diseases, Cambridge, Massachusetts, USA
    J Virol 87:1544-53. 2013
    ..The effect of specific resistant variant frequency on response to various DAA treatments in different patient populations, including interferon nonresponders, should be further studied...
  9. ncbi Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha
    Yi Zhou
    Vertex Pharmaceuticals Inc, Cambridge, Massachusetts 02139, USA
    J Biol Chem 282:22619-28. 2007
    ..Finally, these variant replicons were shown to have reduced replication capacity compared with the wild-type HCV replicon in cells...
  10. pmc A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants
    Bambang S Adiwijaya
    Vertex Pharmaceuticals Incorporated, Cambridge, Massachusetts, United States of America
    PLoS Comput Biol 6:e1000745. 2010
    ..The modeling fitness estimates were robust in sensitivity analyses in which the restoration dynamics of replication space and assumptions of HCV mutation rates were varied...
  11. pmc Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials
    Tara L Kieffer
    Vertex Pharmaceuticals Incorporated, Cambridge, Massachusetts, United States of America
    PLoS ONE 7:e34372. 2012
    ..However, genotypic changes could be observed in TVR-treated patients who did not achieve an SVR...
  12. pmc Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease
    Robert B Perni
    Vertex Pharmaceuticals Incorporated, 130 Waverly Street, Cambridge, Massachusetts 02139, USA
    Antimicrob Agents Chemother 50:899-909. 2006
    ..Therefore, the overall preclinical profile of VX-950 supports its candidacy as a novel oral therapy against hepatitis C...
  13. ncbi Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients
    Tara L Kieffer
    Vertex Pharmaceuticals Inc, Cambridge, MA 02139, USA
    Hepatology 46:631-9. 2007
    ....
  14. pmc Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells
    Kai Lin
    Vertex Pharmaceuticals Incorporated, Cambridge, Massachusetts 02139, USA
    Antimicrob Agents Chemother 48:4784-92. 2004
    ....
  15. doi Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs)
    Tara L Kieffer
    Vertex Pharmaceuticals Inc, 130 Waverly Street, Cambridge, MA 02139, USA
    J Antimicrob Chemother 65:202-12. 2010
    ..Future potential therapeutic strategies to address patients who do develop resistance to STAT-Cs are discussed, including combination therapy with multiple STAT-Cs with non-overlapping resistance profiles...
  16. ncbi In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms
    Chao Lin
    Vertex Pharmaceuticals Inc, Cambridge, Massachusetts 02139, USA
    J Biol Chem 279:17508-14. 2004
    ..Modeling analysis suggests that there are different mechanisms of resistance to VX-950 and BILN 2061...
  17. ncbi Viral and cellular RNA helicases as antiviral targets
    Ann D Kwong
    Vertex Pharmaceuticals Inc, 130 Waverly Street, Cambridge, Massachusetts 02139, USA
    Nat Rev Drug Discov 4:845-53. 2005
    ....
  18. ncbi Inhibitors of hepatitis C virus NS3.4A protease: an overdue line of therapy
    Robert B Perni
    Vertex Pharmaceuticals Inc, 130 Waverly Street, Cambridge, MA 02139, USA
    Prog Med Chem 39:215-55. 2002
  19. pmc Restoration of the activated Rig-I pathway in hepatitis C virus (HCV) replicon cells by HCV protease, polymerase, and NS5A inhibitors in vitro at clinically relevant concentrations
    Gururaj Kalkeri
    Vertex Pharmaceuticals Incorporated, Cambridge, Massachusetts, USA
    Antimicrob Agents Chemother 57:4417-26. 2013
    ....